BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations

BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.